PlumX Metrics
Embed PlumX Metrics

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors

Journal of Clinical Oncology, ISSN: 0732-183X, Vol: 24, Issue: 7, Page: 1037-1044
2006
  • 506
    Citations
  • 0
    Usage
  • 142
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    506
    • Citation Indexes
      503
    • Policy Citations
      2
      • Policy Citation
        2
    • Clinical Citations
      1
      • PubMed Guidelines
        1
  • Captures
    142

Article Description

Purpose: To evaluate whether hormonal receptor (HR) status can influence the prognostic significance of pathologic complete response (pCR). Patients and Methods: This retrospective analysis included 1,731 patients with stage I to III noninflammatory breast cancer treated between 1988 and 2005 with primary chemotherapy (PC). Ninety-one percent of patients received anthracycline-based PC, and 66% received additional taxane therapy. pCR was defined as no evidence of invasive tumor in the breast and axillary lymph nodes. Results: Median age was 49 years (range, 19 to 83 years). Sixty-seven percent of patients (n = 1,163) had HR-positive tumors. A pCR was observed in 225 (13%) of 1,731 patients; pCR rates were 24% in HR-negative tumors and 8% in HR-positive tumors (P < .001). A significant survival benefit for patients who achieved pCR compared with no pCR was observed regardless of HR status. In the HR-positive group, 5-year overall survival (OS) rates were 96.4% v 84.5% (P = .04) and 5-year progression-free survival (PFS) rates were 91.1% v 65.3% (P < .0001) for patients with and without pCR, respectively. For the HR-negative group, 5-year OS rates were 83.9% v 67.4% (P = .003) and 5-year PFS rates were 83.4% v 50.0% (P < .0001) for patients with and without pCR, respectively. After adjustment for adjuvant hormonal treatment, HR status, clinical stage, and nuclear grade, patients who achieved a pCR had 0.36 times the risk of death. Conclusion: pCR is associated with better outcome regardless of HR status in breast cancer patients who receive PC. © 2006 by American Society of Clinical Oncology.

Bibliographic Details

Guarneri, Valentina; Broglio, Kristine; Kau, Shu-Wan; Cristofanilli, Massimo; Buzdar, Aman U; Valero, Vicente; Buchholz, Thomas; Meric, Funda; Middleton, Lavinia; Hortobagyi, Gabriel N; Gonzalez-Angulo, Ana M

American Society of Clinical Oncology (ASCO)

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know